Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
Abstract
OBJECTIVE—We examined metabolic changes in the period immediately after the diagnosis of type 1 diabetes and in the period leading up to its diagnosis in Diabetes Prevention Trial–Type 1 (DPT-1) participants.
RESEARCH DESIGN AND METHODS—The study included oral insulin trial participants and parenteral insulin trial control subjects (n = 63) in whom diabetes was diagnosed by a 2-h diabetic oral glucose tolerance test (OGTT) that was confirmed by another diabetic OGTT within 3 months. Differences in glucose and C-peptide levels between the OGTTs were assessed.
RESULTS—Glucose levels increased at 90 (P = 0.006) and 120 min (P < 0.001) from the initial diabetic OGTT to the confirmatory diabetic OGTT (mean ± SD interval 5.5 ± 2.8 weeks). Peak C-peptide levels fell substantially between the OGTTs (median change −14.3%, P < 0.001). Among the 55 individuals whose last nondiabetic OGTT was ∼6 months before the initial diabetic OGTT, peak C-peptide levels decreased between these two OGTTs (median change −14.0%, P = 0.052). Among those same individuals the median change in peak C-peptide levels from the last normal OGTT to the confirmatory OGTT (interval 7.5 ± 1.3 months) was −23.8% (P < 0.001). Median rates of change in peak C-peptide levels were 0.00 ng · ml−1 · month−1 (P = 0.468, n = 36) from ∼12 to 6 months before diagnosis, −0.10 ng · ml−1 · month−1 (P = 0.059, n = 55) from 6 months before diagnosis to diagnosis, and −0.43 ng · ml−1 · month−1 (P = 0.002, n = 63) from the initial diabetic OGTT to the confirmatory diabetic OGTT.
CONCLUSIONS—It seems that postchallenge C-peptide levels begin to decrease appreciably in the 6 months before diagnosis and decrease even more rapidly within 3 months after diagnosis.
Footnotes
-
Published ahead of print at http://care.diabetesjournals.org on 23 July 2008.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
- Accepted July 19, 2008.
- Received May 20, 2008.
- DIABETES CARE